SLC29A2 and colorectal carcinoma: The data of the early stage of CRC cell line, HT29/KO, confirmed this phenomenon, i.e., increased XO activity was concurrent with the significant elevation of ROS level by 1.58-fold in the partial ENT2 knockout clone (HKO1) and 1.66-fold in the complete ENT2 knockout clone (HKO2).